The complexity of MS highlights the need for reliable, accessible biomarkers to improve disease management. Blood-based biomarkers provide a minimally invasive, cost-effective, scalable way to monitor disease activity (DA) and guide personalized treatment. They can identify inflammatory and neurodegenerative processes, track treatment response, and detect subclinical activity. Integrating them into routine care may enhance early diagnosis, optimize therapy, and improve long-term outcomes.

The MSDA Test has been commercially available since 2022. By September 2025, 21,138 tests were ordered from 198 institutions, 359 providers, in 15,040 MS patients. Baseline demographics include mean age of 52.0 years, 77.0% female, 76.8% White, 14.7% Black, and 4.4% Hispanic.

Among patients with DMT data, 44.4% were on high-efficacy DMTs (anti-CD20s, natalizumab, cladribine, alemtuzumab) at their latest test; 34.2% were not on a DMT. DA scores were 65.2% low, 28.5% moderate and 6.3% high (mean 4.0). 71.5% patients had 1 test, 20.8% had 2, and 7.7% had ≥3 tests. For patients with ≥2 tests ≥3 months apart, mean DA score changes exceeded the 1.24 minimum detectable change for previously high scores. Top HCP-reported indications for testing included routine monitoring, therapy assessment, DMT response, and baseline evaluation.